Stakeholders involved in the setup and running of Parkinson’s platform trials met recently for the second annual International PD-Platform Meeting, leading to the launch of the Global Alliance for Parkinson’s Platforms (GAPP). Representatives from the UK, France, the US, Norway, and Australia have joined this new international initiative.
GAPP has been created through collaboration between Cure Parkinson’s and France Parkinson. The alliance aims to accelerate the development of disease-modifying treatments for Parkinson’s by strengthening coordination across platform trials worldwide.
Platform trials are a major advancement in Parkinson’s research because they allow multiple potential treatments to be tested within a single, flexible framework. This approach offers a faster and more efficient route to evaluate therapies that may slow or stop disease progression. GAPP’s purpose is to ensure that these efforts are aligned internationally rather than running in isolation.
The alliance will share resources, harmonise study procedures, involve people living with Parkinson’s, and align data standards. Working groups are focused on drug preparedness, data harmonisation, biomarkers, long-term sustainability, and public and patient involvement and engagement. By reducing duplication and supporting smart drug selection, GAPP aims to promote shared learning and improve understanding of regulatory trends across countries.
| Sign up to the ACNR email newsletter here |
A key goal is to strengthen global engagement with industry partners. Platform trials depend on a pipeline of promising therapeutic candidates. By providing a unified framework, GAPP aims to make it easier for biotech and pharmaceutical companies to collaborate with multiple platforms, contribute candidate drugs, and form partnerships across regions.
By connecting national initiatives into a coordinated global effort, GAPP aims to increase the scientific impact of each platform and create a clearer path from early discovery to late-phase trials. The alliance seeks to build a more efficient and hopeful future for Parkinson’s research, helping deliver effective treatments to people sooner.
Source:
Cure Parkinson’s press release
| Sign up for our online community for neurology specialists |
